[{"address1": "9708 Medical Center Drive", "city": "Rockville", "state": "MD", "zip": "20850", "country": "United States", "phone": "240 243 1201", "fax": "301 738 2137", "website": "https://www.glycomimetics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.", "fullTimeEmployees": 35, "companyOfficers": [{"maxAge": 1, "name": "Mr. Harout  Semerjian", "age": 53, "title": "CEO, President & Director", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 1126090, "exercisedValue": 0, "unexercisedValue": 465102}, {"maxAge": 1, "name": "Ms. Rachel K. King", "age": 64, "title": "Co-Founder & Director", "yearBorn": 1959, "fiscalYear": 2023, "totalPay": 40000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Brian M. Hahn", "age": 49, "title": "Senior VP & CFO", "yearBorn": 1974, "fiscalYear": 2023, "totalPay": 822117, "exercisedValue": 0, "unexercisedValue": 98649}, {"maxAge": 1, "name": "Dr. Edwin  Rock M.D., Ph.D.", "age": 62, "title": "Senior VP & Chief Medical Officer", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 677399, "exercisedValue": 0, "unexercisedValue": 101250}, {"maxAge": 1, "name": "Ms. Stephanie R. Irish CPA", "age": 52, "title": "Vice President of Accounting", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christian B. Dinneen-Long", "title": "General Counsel & Company Secretary", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bruce  Johnson", "age": 55, "title": "Senior VP & Chief Commercial Officer", "yearBorn": 1968, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Chinmaya  Rath", "age": 46, "title": "Senior VP & Chief Business Officer", "yearBorn": 1977, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Shantha  Tyavanagimatt Ph.D.", "title": "Senior Vice President of Technical Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 6, "compensationRisk": 7, "shareHolderRightsRisk": 9, "overallRisk": 7, "governanceEpochDate": 1717200000, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 0.2603, "open": 0.266, "dayLow": 0.251, "dayHigh": 0.2669, "regularMarketPreviousClose": 0.2603, "regularMarketOpen": 0.266, "regularMarketDayLow": 0.251, "regularMarketDayHigh": 0.2669, "beta": 2.143, "forwardPE": -0.572, "volume": 577592, "regularMarketVolume": 577592, "averageVolume": 1723295, "averageVolume10days": 1020600, "averageDailyVolume10Day": 1020600, "bid": 0.2538, "ask": 0.262, "bidSize": 200, "askSize": 200, "marketCap": 16593137, "fiftyTwoWeekLow": 0.25, "fiftyTwoWeekHigh": 3.53, "priceToSalesTrailing12Months": 1659.3137, "fiftyDayAverage": 1.2942, "twoHundredDayAverage": 1.9116, "currency": "USD", "enterpriseValue": -14057493, "floatShares": 40479138, "sharesOutstanding": 64464400, "sharesShort": 2336815, "sharesShortPriorMonth": 3012763, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.0363, "heldPercentInsiders": 0.0308, "heldPercentInstitutions": 0.5181, "shortRatio": 0.69, "shortPercentOfFloat": 0.0523, "impliedSharesOutstanding": 64464400, "bookValue": 0.449, "priceToBook": 0.57327396, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -37276736, "trailingEps": -0.58, "forwardEps": -0.45, "enterpriseToRevenue": -1405.749, "enterpriseToEbitda": 0.357, "52WeekChange": -0.8586956, "SandP52WeekChange": 0.23232913, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "GLYC", "underlyingSymbol": "GLYC", "shortName": "GlycoMimetics, Inc.", "longName": "GlycoMimetics, Inc.", "firstTradeDateEpochUtc": 1389364200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "efe04473-e4ee-3464-8e89-48cc4b8490b8", "messageBoardId": "finmb_5703481", "gmtOffSetMilliseconds": -14400000, "currentPrice": 0.2574, "targetHighPrice": 1.0, "targetLowPrice": 0.5, "targetMeanPrice": 0.75, "targetMedianPrice": 0.75, "recommendationMean": 2.2, "recommendationKey": "buy", "numberOfAnalystOpinions": 2, "totalCash": 31281460, "totalCashPerShare": 0.485, "ebitda": -39325220, "totalDebt": 630827, "quickRatio": 5.929, "currentRatio": 6.284, "totalRevenue": 10000, "debtToEquity": 2.182, "returnOnAssets": -0.47817, "returnOnEquity": -0.81844, "freeCashflow": -20966836, "operatingCashflow": -33781872, "grossMargins": 1.0, "operatingMargins": -3944.9304, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-10"}]